Skip to main content
. 2020 Feb 21;2020:8797683. doi: 10.1155/2020/8797683

Figure 7.

Figure 7

Comparison of plasma and PF IL-17A concentration in patients with ovarian cancer (a) or in the group with benign ovarian tumors (b).